Oncotarget


2023 Press Releases

Oncotarget | Intraventricular Immunovirotherapy; A Translational Step Forward


FOR IMMEDIATE RELEASE
2023-01-26

“Immunotherapies, including oncolytic virotherapy, offer novel, targeted approaches to treat brain tumors with increased efficacy and reduced toxicity [5].” 


BUFFALO, NY- January 26, 2023 –
A new research perspective was published in Oncotarget's Volume 14 on January 12, 2023, entitled, “Intraventricular immunovirotherapy; a translational step forward.”

In this new perspective, researchers Joshua D. Bernstock, Sarah Blitz, Kyung-Don Kang, and Gregory K. Friedman from Harvard Medical School, Mass... continue reading >>

Oncotarget | The Chromatographic Constitution of Andiroba Oil and its Healing Effects…


FOR IMMEDIATE RELEASE
2023-01-24

“The andiroba extract in wounds provides acceleration in healing process, with increase of contraction rate and local re-epithelialization, resulting in the complete closure of wounds [52].” 

BUFFALO, NY- January 24, 2023 – A new research paper was published in Oncotarget's Volume 14 on January 12, 2023, entitled, “The chromatographic constitution of andiroba oil and its healing effects, compared to the LLLT outcomes, in oral mucositis induced in golden Syrian hamsters: a new treatment option.”... continue reading >>

Oncotarget | Targeting CD74 in B-Cell Non-Hodgkin Lymphoma With Antibody-Drug Conjugate STRO-001


FOR IMMEDIATE RELEASE
2023-01-17

“Taken together, these findings provide a strong rationale for potently and selectively targeting of CD74 in patients with B-NHL [B-cell non-Hodgkin lymphoma].”

BUFFALO, NY- January 17, 2023 – A new research paper was published in Oncotarget's Volume 14 on January 12, 2023, entitled, “Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001.”

Overexpression of CD74, a type II transmembrane glycoprotein involved in MHC class II antigen presentation, has been... continue reading >>

Oncotarget | Calcium Signaling Induced by 15-deoxy-prostamide-J2 Promotes Cell Death by...


FOR IMMEDIATE RELEASE
2023-01-12

“The goal of the present study was to determine the therapeutic potential of 15d-PMJ2 against melanoma by gaining insight into molecular mechanisms underlying its apoptotic activity.” 


BUFFALO, NY- January 12, 2023 –
A new research paper was published in Oncotarget's Volume 13 on December 29, 2022, entitled, “Calcium signaling induced by 15-deoxy-prostamide-J2 promotes cell death by activating PERK, IP3R, and the mitochondrial permeability transition pore.”

 

Melanoma is the deadliest form of... continue reading >>

Oncotarget | Impact of Covid-19 on Management of Patients With Metastatic Melanoma


FOR IMMEDIATE RELEASE
2023-01-11

“In this study, we aimed to analyze our experience with patients suffering from Sars-CoV-2 infection while receiving treatment for metastatic melanoma.” 


BUFFALO, NY- January 11, 2023 –
A new research paper was published in Oncotarget's Volume 13 on December 29, 2022, entitled, “Impact of Covid-19 on the management of patients with metastatic melanoma.”

 

The Covid-19 pandemic created new uncertainties in the management of metastatic melanoma patients. In particular, the impact of... continue reading >>

Oncotarget | Resistance of MMTV-NeuT/ATTAC Mice to Anti-PD-1 Immune Checkpoint Therapy Associated With Macrophage Infiltration and Wnt Pathway Expression


FOR IMMEDIATE RELEASE
2023-01-05

“One of the impediments to successful cancer therapy is the heterogeneity and cellular plasticity of the tumor and TME [22, 23].” 


BUFFALO, NY- January 5, 2023 –
A new research paper was published in Oncotarget's Volume 13 on December 20, 2022, entitled, “Resistance of MMTV-NeuT/ATTAC mice to anti-PD-1 immune checkpoint therapy is associated with macrophage infiltration and Wnt pathway expression.”

 

One of the central challenges for cancer therapy is the identification of factors in the tumor... continue reading >>



Copyright © 2023 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC